Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Promising Efficacy from Elacytarabine/idarubicin Combination in Phase II AML Study

Published: Monday, December 10, 2012
Last Updated: Monday, December 10, 2012
Bookmark and Share
Data presented at the American Society of Hematology annual meeting.

Clavis Pharma ASA has announced data from its Phase II clinical trial with elacytarabine in combination with idarubicin.

The trial enrolled patients with early stage acute myeloid leukaemia (AML), for whom cytarabine-containing first-course chemotherapy has failed and results were presented by Dr David Rizzieri from Duke University Medical Center at the American Society of Haematology annual meeting in Atlanta, GA.

Elacytarabine is a novel, patented lipid-conjugated form of the anti-cancer drug cytarabine, which is routinely used in the treatment of AML.

The results found that treatment with the elacytarabine/idarubicin combination showed promising clinical activity with a complete remission (CR/CRi) rate of approximately 43% in patients who failed to respond to first-course treatment (20 of 46 evaluable patients).

To date, 13 patients were deemed fit enough following treatment to be referred for stem cell transplantation, which represents a potential cure for these patients.

The safety profile is consistent with this type of cytotoxic therapies.

The main objective of the 51-patient trial is to demonstrate that patients failing cytarabine can be rescued by elacytarabine. The study was conducted at leading haematology clinics in the USA and Europe.

Olav Hellebø, Clavis Pharma CEO, commented: "The results have shown that elacytarabine in combination with idarubicin elicits a therapeutic effect in a substantial proportion of early stage AML patients for whom first-course cytarabine treatment failed. This is very encouraging and highlights the potential of elacytarabine to offer a new treatment option to patients who may not respond to current standard cytarabine-containing therapies. We would like to thank the investigators and their patients for taking part in this study.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Clavis Pharma Completes Patient Recruitment in Phase III CLAVELA Study in AML Patients
Top-line data are expected to be available in Q1 2013.
Thursday, December 06, 2012
Clavis Pharma Announces Results of the LEAP Study of CP-4126 in Metastatic Pancreatic Cancer
Clavis Pharma continues to focus on elacytarabine and its Phase III CLAVELA study in leukaemia patients.
Monday, November 19, 2012
Clavis Pharma Provides Update on Pivotal LEAP Trial with CP-4126
64% of the 360 patients enrolled in the study are hENT1-low.
Monday, October 22, 2012
Clavis Pharma Announces Size of Initial hENT1-low Population in Pivotal LEAP Trial with CP-4126
65 percent of the initial 250 patients enrolled in the study are hENT1-low.
Monday, March 05, 2012
Clavis Pharma - Update Regarding Phase III CLAVELA Trial
Top line results are expected in the first quarter of 2013, one quarter delayed.
Tuesday, January 17, 2012
Clovis Oncology Expands the Observational Study to Determine Patient Stratification in Pivotal LEAP Clinical Trial with CP-4126
New, improved hENT1 biomarker assay developed.
Monday, January 02, 2012
Clavis Pharma Announces the Completion of Study 002
Low hENT1 cut-off level determined for pivotal LEAP study of CP-4126 in patients with pancreatic cancer.
Friday, October 28, 2011
Clavis Pharma Second Quarter and First Half Report 2011
Clavis Pharma and Clovis Oncology expanded the LEAP study, evaluating CP-4126 vs. gemcitabine in pancreatic cancer patients.
Friday, August 26, 2011
Clavis Pharma Expands Phase III CLAVELA Study in Patients With Acute Myeloid Leukaemia
Top line data are now expected to be available in Q4 2012.
Friday, August 26, 2011
Clavis Pharma’s CP-4126 Enters New Phase II Clinical Trial in Pancreatic Cancer Patients
The trial will investigate the use of CP-4126 as a 2nd line treatment for advanced, metastatic pancreatic cancer in patients refractory to 1st line gemcitabine treatment.
Friday, February 04, 2011
Clavis Pharma and Clovis Oncology Extend Partnership and Sign new $205 Million Deal
Partnership is aimed for the development and commercialization of anti-cancer agent CP-4126 in Asia and rest of the World.
Friday, November 12, 2010
Scientific News
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!